title: Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.
authors.affiliation: BCSH, British Society for Haematology, London, UK.
authors.forename: C A
authors.initials: CA
authors.lastname: Ludlam
authors.forename: B
authors.initials: B
authors.lastname: Bennett
authors.forename: K A
authors.initials: KA
authors.lastname: Fox
authors.forename: G D
authors.initials: GD
authors.lastname: Lowe
authors.forename: A W
authors.initials: AW
authors.lastname: Reid
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D012307:Risk Factors; D013300:Streptokinase / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator